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Abstract
Background: Glucocorticoid therapy is the most common cause of iatrogenic osteoporosis. Less is known
regarding the effect of glucocorticoids when used as replacement therapy on bone remodelling in patients with
adrenal insufficiency. Enhanced intracellular conversion of inactive cortisone to active cortisol, by 11 beta-
hydroxysteroid dehydrogenase type 1(11β-HSD1) and other enzymes leading to alterations in glucocorticoid
metabolism, may contribute to a deleterious effect on bone health in this patient group.
Methods: Study design: An open crossover prospective study randomizing ten hypopituitary men, with severe
ACTH deficiency, to three commonly used hydrocortisone dose regimens.
Measurements: Following 6 weeks of each regimen, patients underwent 24-h serum cortisol/cortisone sampling,
measurement of bone turnover markers, and a 24-h urine collection for measurement of urinary steroid metabolites
by gas chromatography-mass spectrometry (GC-MS). Serum cortisone and cortisol were analysed by liquid
chromatography-mass spectrometry (LC-MS).
Results: Dose-related and circadian variations in serum cortisone were seen to parallel those for cortisol, indicating
conversion of ingested hydrocortisone to cortisone. The median area under the curve (AUC) of serum cortisone was
significantly higher in patients on dose A (20mg/10mg) [670.5 (IQR 621–809.2)] compared to those on dose C (10mg/5
mg) [562.8 (IQR 520.1–619.6), p = 0.01]. A negative correlation was observed between serum cortisone and bone
formation markers, OC [1–49] (r = − 0.42, p = 0.03), and PINP (r = − 0.49, p = 0.01). There was a negative correlation
between the AUC of night-time serum cortisone levels with the bone formation marker, OC [1–49] (r = − 0.41, p = 0.03)
but there were no significant correlations between day-time serum cortisone or cortisol with bone turnover markers.
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There was a negative correlation between total urinary cortisol metabolites and the bone formation markers, PINP (r = −
0.39, p = 0.04), and OC [1–49] (r = − 0.35, p = 0.06).
Conclusion: Serum cortisol and cortisone and total urinary corticosteroid metabolites are negatively associated with bone
turnover markers in patients receiving replacement doses of hydrocortisone, with nocturnal glucocorticoid exposure
having a potentially greater influence on bone turnover.
Trial registration: Irish Medicines Board Clinical Trial Number – CT900/459/1 and EudraCT Number – 2007-005018-37.
Registration date: 07-09-2007.
Keywords: Cortisone, Cortisol, Bone turnover markers, Hypopituitarism, Metabolites, Adrenal insufficiency
Background
Glucocorticoids are widely used in the treatment of
inflammatory, allergic, immunologic and malignant disor-
ders. In adrenal insufficiency, glucocorticoids are given at
doses intended to mimic the physiological concentrations
and circadian rhythm of cortisol secretion [1]. Treatment of
adrenal insufficiency consists of two or three daily oral
doses of immediate-release hydrocortisone, which has a
short half-life. As we and others have previously shown, this
can result in serum cortisol peaks above and troughs below
physiological levels [2–5]. Long-term over-replacement
(even at relatively low exposure) of glucocorticoid therapy
(as seen in iatrogenic Cushing’s syndrome) can cause
weight gain, glucose intolerance and abnormal bone metab-
olism, leading to osteoporosis [6–8].
The deleterious effects of endogenous and exogenous
glucocorticoid excess on bone health are well recog-
nized. The risk of bone loss is greatest in the first few
months following initiation of therapy, followed by a
slower rate of loss with chronic use [9]. There is an
increased risk of fractures associated with therapeutic
immunosuppressive glucocorticoid therapy, and fractures
occur at a higher bone mineral density (BMD) than that
reported in postmenopausal osteoporosis [10].
Less literature exists on the effect of glucocorticoids
used as replacement therapy for adrenal insufficiency on
bone remodelling [11–14]. Some studies reported reduced
BMD in all patients with primary adrenal insufficiency
[12, 15] and other studies reporting this effect only in
postmenopausal women receiving hydrocortisone replace-
ment [16] or only in men [11, 17]. There is a paucity of
data on the effect of glucocorticoid replacement on bone
metabolism in patients with adrenocorticotropin (ACTH)
deficiency/ secondary adrenal insufficiency. Peacey et al.
demonstrated that a reduction in glucocorticoid dose by
30%, to 20mg of hydrocortisone per day, was associated
with a 19% increase in the bone formation marker osteo-
calcin (OC [1–49]) and a weak but significant negative
correlation between absolute BMD and dose of hydrocor-
tisone (HC) replacement [18]. Wichers et al. also demon-
strated a significant increase in OC [1–49] as the dose of
hydrocortisone decreased from 30mg to 15mg, however,
there was no control group and no comment on the
replacement status of the other pituitary hormones, which
can have significant effects on bone health [19]. We have
recently shown that there is an increase in OC [1–49]
concentrations when the daily dose of hydrocortisone is
decreased from 30mg to 15mg in a well-characterised
cohort of hypopituitary patients on stable hormonal re-
placement therapy [20].
Several studies have shown, that in healthy controls,
endogenous cortisol secretion is associated with BMD
and the rate of bone loss. This has been assessed by
serum cortisol measurement [21], dynamic testing of the
hypothalamic-pituitary-adrenal axis [22], salivary cortisol
assessments [23, 24], and by urinary free cortisol [25].
Other authors have found the circadian rhythm of bone
formation (but not of bone resorption) can be modified
by changing cortisol circadian rhythm [26–28].
In recent years, our knowledge of glucocorticoid action
has expanded with the characterization of enzymes that
regulate glucocorticoid action at the tissue level. The
isoenzymes of the 11 beta-hydroxysteroid dehydrogenase
system (11β-HSD) are responsible for intracellular
glucocorticoid availability and are expressed in human
synovial tissue and bone [29]. 11β-HSD type 2 converts
the hormonally active cortisol (F) to inactive cortisone
(E). In patients with ACTH deficiency, circulating corti-
sone is generated through 11β-HSD type 2 activity on
ingested exogenous hydrocortisone therapy. In contrast,
11β-HSD type 1 converts the inactive glucocorticoid corti-
sone to active cortisol. 11β-HSD1 is expressed in human
adult bone and cultured primary osteoblasts [30, 31].
Enhanced intracellular conversion of cortisone to
cortisol may contribute to a deleterious effect on bone
mineral density, an assumption supported by the pres-
ence of polymorphisms within the HSD11B1 gene en-
coding 11β-HSD1 associated with low BMD and fracture
risk in postmenopausal women without hypercortisolism
[32]. Also, bone-specific responses to glucocorticoids
have been shown to correlate with serum cortisone.
Therefore, the presence of a tissue-specific conversion of
inactive cortisone to active cortisol (i.e. 11β-HSD1) may
be potentially biologically relevant [33].
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On this background, our hypothesis was that circulating
cortisone and tissue-specific metabolism of glucocorti-
coids impacts negatively on bone health in hypopituitary
patients receiving hydrocortisone replacement therapy.
Our study aimed to examine in a prospective, cross-
over randomized controlled manner in a group of male
hypopituitary patients:
1. The daily cortisone and cortisol profile in patients
receiving hydrocortisone therapy (previous studies
have focused only on cortisol, not cortisone)
2. To assess the impact of different dosing regimens
on bone turnover markers and compare this to
healthy controls.
3. The association between serum cortisone and




Ten adult male hypopituitary patients with known
ACTH deficiency on dynamic testing were included in a
randomized, controlled, crossover study of three different
HC replacement regimens (results related to other aspects
of this study have been published previously) [5, 20, 34].
Patients had been diagnosed and treated for pituitary
tumours between 3 and 18 years before inclusion in the
study.
The inclusion and exclusion criteria for study entry
have been previously published [20]. Briefly, all patients
were on stable appropriate pituitary hormone replace-
ment, including growth hormone, without alteration in
the dose for at least 3 months before and for the dur-
ation of the study. Hormone replacement therapy regi-
mens were not adjusted during the study period, except
for hydrocortisone dose, as per study protocol. Patients
were matched for age, BMI and waist circumference
with control subjects. No patient was taking calcium or
vitamin D supplementation. Exclusion criteria included
conditions associated with altered bone turnover such as
Paget’s disease or known osteoporosis or fracture within
the previous 1 year. We excluded patients on glucocorti-
coids for purposes other than ACTH deficiency and
those on agents that interfere with corticosteroid or
bone metabolism.
All patients were recruited through the pituitary clinic
in Beaumont Hospital, Dublin, Ireland.
Study design
The study design has been previously published [5, 20,
34, 35]. Subjects were randomized to a crossover proto-
col (in random order) of three commonly prescribed
doses of HC; dose A – 20mg 08.00 hours, 10mg 16.00
hours; dose B – 10mg 08.00 hours, 10mg 16.00 hours
and dose C – 10mg 08.00 h, 5mg 16.00 hours. These
doses are frequently used in clinical practice [36]. At
baseline and the end of each 6-week treatment schedule,
patients were admitted, fasting, to the Clinical Research
Facility at 07.30 h for 28 h. They underwent a physical
examination that included blood pressure, weight,
height, and waist circumference measurement. Following
this examination, an 18 g cannula was placed in the
antecubital fossa under aseptic technique. Basal samples
were taken for cortisol, cortisol binding globulin (CBG),
free T4, TSH, testosterone, gonadotropins, prolactin and
insulin-like growth factor-I (IGF-I), parathyroid hormone
(PTH), 25-hydroxyvitamin D (25 [OH] D), calcium, albu-
min and renal function. The cannula was then flushed
with 10mls of a heparinised solution (heparin sodium,
100 units diluted in 100mls of 0.9% normal saline) to
maintain patency for the full 28-h period. The use of
diluted heparin in this manner does not affect any of the
laboratory sampling techniques used subsequently [37]
and since the first 5 ml of blood withdrawn at each time
point was discarded there was little chance of contamin-
ation with such dilute levels of heparin. During this period
the subjects had serum cortisol samples taken hourly
through the indwelling cannula from the time of admis-
sion until midnight and were taken two-hourly from mid-
night until 0800 h the following morning.
Patients took the designated hydrocortisone dose that
they had been taking for the preceding 6 weeks at 0800 h
just after admission, at 1600 h and 0800 h the next
morning. Meals were eaten at pre-defined times and
lights were turned off at 23.00 h. The samples were
allowed to stand at room temperature for 30 min to fa-
cilitate clotting before being centrifuged at 3000 rpm for
15min, stored in 1 ml aliquots and frozen at − 20 and
-80degrees centigrade for cortisol and CBG respectively
until analysis.
The control participants for this study were ten healthy
males, matched for age, BMI and waist circumference that
underwent the same biochemical investigations and clin-
ical examination but did not take exogenous cortisol.
Additionally, patients and controls performed a 24-urine
collection for measurement of urinary steroid metabolites.
Data regarding quality of life and serum cortisol
profiles and the relationship with serum cortisol (but
not cortisone or corticosteroid metabolites) and bone
markers in this patient group have previously been pub-
lished [5, 20, 34].
Analytical methods
Bone markers and bone Remodelling
OC [1–49], CTX-I and PINP were measured using an
electrochemiluminescence immunoassay on the Elecsys
2010 analyser (Roche Diagnostics, Mannheim, Germany)
as previously described [20]. Bone ALP, a marker of both
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bone mineralisation and maturation was measured by an
immunoenzymatic assay [20]. TRACP5b was measured
by ELISA (Immunodiagnostic Systems Ltd., Boldon, UK)
[20]. We calculated the PINP: CTX-I ratio as an ap-
proximation of bone remodelling balance [20].
Serum cortisone/ cortisol analysis by tandem mass
spectrometry
Serum cortisol and cortisone were analysed by liquid
chromatography-mass spectrometry following protein
precipitation as previously described [38]. For cortisol,
performance characteristics were as previously described
[38]. For cortisone, inter-assay imprecision was 5.5, 3.9
and 3.8% at concentrations of 5.0, 50.0 and 150 nmol/L
respectively. The limit of quantitation was determined to
be 2.5 nmol/L and the assay was free from analytical
interferences.
The area under the cortisone time curves in each pa-
tient (an estimate of the total circulating cortisone) was
measured. We investigated the diurnal variation in circu-
lating cortisone among the study population. Day-time
serum cortisone was defined as the AUC of all serum
samples taken from 08:00 until 19:00 inclusive. Night-
time serum cortisone included all serum samples taken
from 20:00 until 08:00 the following morning.
Urinary corticosteroid metabolite profiling by gas
chromatography-mass spectrometry
Corticosteroid metabolites were analysed using urinary
gas chromatography-mass spectrometry (GC-MS). GC-
MS urinary steroid analysis was carried out in the Steroid
Metabolome Analysis Core at the Institute of Metabolism
and Systems Research, the University of Birmingham
using previously reported methodology [39, 40]. Thirty-
two steroids were targeted for selected-ion-monitoring
analysis, including metabolites of androgens, mineralocor-
ticoids and glucocorticoids (and their precursors).
The ratio of THF + 5α-THF/THE was used as a
marker of 11β-HSD1 activity, providing the UFF/UFE
ratio (reflecting 11β-HSD2 activity) was normal. Sum-
mation of THF + 5α-THF + THE + cortols + cortolones
+ UFF + UFE was used as a surrogate marker of 24-h
total cortisol metabolites as previously validated [41].
Other biochemical indices
Serum 25OH-Vitamin D was measured by a competitive
radioimmunoassay (Immunodiagnostic Systems Ltd.,
Boldon, UK) as previously described [20]. Serum PTH
was measured using an electrochemiluminescent immuno-
assay on the Elecsys 2010 analyser (Roche Diagnostics,
Mannheim, Germany) as described previously [20]. Renal
function, albumin and calcium were measured using the
Beckman Coulter AU5400 by standard laboratory proto-
cols. Serum IGF-1, thyroid function, testosterone, prolactin
concentrations were assessed using standard methodology
as previously described [5].
Statistical methods
Statistical analysis was performed using Prism for Win-
dows version 5.0 (GraphPad Software, Inc., San Diego,
CA, USA) software. Continuous data were summarized
using means and S.D.s (or S.E.M.) if parametrically
distributed or medians and inter-quartile ranges if non-
parametrically distributed. Parametric data were com-
pared using a paired t-test and non-parametric data were
analysed using a Mann–Whitney test. Multiple compari-
sons were assessed using one-way ANOVA, with Krus-
kal–Wallis for non-parametric data. Repeated measures
analysis was performed using the Friedman test and
Dunn’s multiple comparison test. Associations between
variables were analysed using Pearson correlation for
parametric data and Spearman rank correlation for non-
parametric data. We calculated that a sample of 7 patients
per group was required for a power of 80% to detect a
significant difference in bone turnover markers, based on
known mean values for a healthy male population [42]
and patients on hydrocortisone replacement therapy [18],




Circadian variations in serum cortisone and cortisol in
healthy controls and study participants receiving the
three different dose regimens of hydrocortisone are
shown in Fig. 1. At 08.00 h, patients with adrenal insuffi-
ciency had significantly lower cortisol [median (IQR) 81
nmol/l (22–157) vs 391.5 nmol/l (326–488.5), p = 0.005]
and cortisone [median (IQR) 20 nmol/l (5-32) vs 64.5
nmol/l (57.3–71.3), p < 0.0001] concentrations than
healthy controls. Patients receiving hydrocortisone ther-
apy had a higher AUC of cortisol [AUC median (IQR)
883.5 (709.5–1360) vs 616 (447.4–847.4), p = 0.019] and
cortisone [AUC median (IQR) 216.5 (174.5–2475) vs
165.8 (132.4–196.4), p = 0.015] concentrations from 18.00
to 24:00, after taking their hydrocortisone at 16:00, com-
pared to controls.
Fluctuations in serum cortisone concentrations in
patients were found to parallel those for cortisol (albeit at
lower concentrations) with peaks and troughs relating to
the dosing schedule, Fig. 1. When data from all patients on
hydrocortisone replacement therapy were analysed, we
found a strong positive correlation between circulating
serum cortisone and serum cortisol (r = 0.93, p = < 0.0001).
The area under the curve (AUC) of 24-h serum corti-
sone concentrations was significantly higher in patients on
dose A (20mg/10mg) [670.5 (IQR 621–809.2)] compared
to those on dose C (10mg/5mg) [562.8 (IQR 520.1–
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619.6), p = 0.01]. There was no significant difference in the
AUC of 24-h serum cortisone concentrations between
dose A (20mg/10mg) [670.5 (IQR 621–809.2)] and dose
B (10mg/10mg) [647.8 nmol/L (IQR 566.9–706.3), p =
0.24] or between dose B (10mg/10mg) [647.8 nmol/L
(IQR 566.9–706.3)] and dose C (10mg/5mg) [562.8
nmol/l (IQR 520.1–619.6), p = 0.09]. Patients on dose B
and dose C had significantly lower 24-h serum cortisone
concentrations than the healthy control group [AUC
742.3 (IQR 696.6–923.3)], p value = 0.01 and p = 0.0003,
respectively. There was no significant difference in serum
cortisone concentrations between patients on dose A (20/
10mgs) compared to the control group (p = 0.10), Fig. 2.
The relationships between serum cortisone/ cortisol and
bone turnover markers
The concentrations of the bone turnover markers in the
study population are detailed in Table 1.
Fig. 1 Mean 24-h serum total cortisol (open circles) and cortisone (closed circles) profile in (a) Controls (b) Group A (c) Group B (d) Group C.
Hydrocortisone doses given at 08.00 h and 16.00 h
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Bone formation
When all patients were combined, a significant negative
correlation was observed between serum cortisone and
bone formation markers, OC [1–49], [r = − 0.42, p =
0.03, Fig. 3a] and PINP [r = − 0.49, p = 0.01), Fig. 3b].
There was a negative correlation seen between serum
cortisol and PINP (r = − 0.36, p = 0.07) but this did not
reach significance, however, a significant negative correl-
ation was shown between serum cortisol and OC [1–49],
(r = − 0.57, p = 0.002), Table 2.
To assess the relative importance of the diurnal
rhythm of cortisone/cortisol, we assessed the diurnal
variation of circulating serum cortisone/cortisol and the
association with bone turnover markers, Table 3. There
was a negative correlation between the AUC of night-
time serum cortisone concentrations with the bone
formation marker, OC [1–49] (r = − 0.41, p = 0.03). Simi-
larly, there was a negative correlation between night-
time serum cortisol with OC [1–49], however, this was
less significant (r = − 0.36, p = 0.07). We also observed
Fig. 2 (a) Area under the curve (AUC) cumulative exposure of 24-h serum cortisone (b) AUC day-time cumulative exposure of cortisone (c) AUC
night-time cumulative exposure of cortisone in patient groups and controls. ns, not significant, p value> 0.05, *p value < 0.05, **p value < 0.01,
***p value< 0.001
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negative correlations between the AUC of night-time
serum cortisone and PINP (r = − 0.34, p = 0.08) and
serum cortisol with PINP (r = − 0.38, p = 0.05). There
was a reciprocal relationship with the AUC of day-time
trough cortisone levels and bone formation markers
PINP (r = − 0.4, p = 0.03) and OC [1–49] (r = − 0.42, p =
0.03) in the patients receiving hydrocortisone, that was
not observed in the control group.
Bone resorption
There was a negative correlation between AUC serum
cortisol and the bone resorption marker CTX-I (r = −
0.5, p = 0.008), Table 2 which was not as strong between
serum cortisone and CTX-I (r = − 0.34, p = 0.08), Fig. 3d.
Both serum cortisone and serum cortisol negatively cor-
related with the bone-remodelling index, PINP: CTX-I
ratio, with a stronger significance observed with serum
cortisol (r = − 0.48, p = 0.012) than with serum cortisone
(r = − 0.39, p = 0.04), Fig. 3f.
Night-time serum cortisone negatively correlated with
CTX-I, but this was not significant (r = − 0.34, p = 0.08).
We did not observe any significant correlations between
day-time and night-time serum cortisone or cortisol
with any other bone resorption markers, Table 3.
Due to the significant correlation between serum corti-
sone and serum cortisol and the small sample size we
were not able to accurately adjust (using multiple regres-
sion analysis) to estimate the impact of each independ-
ent variable on bone turnover markers.
Urinary cortisol metabolites and bone turnover markers
Dose A (20mg/10mg) was associated with significantly
higher total urinary cortisol (F) metabolites compared to
the other dose regimens (P < 0.05 vs dose B, P < 0.001 vs
dose C) and healthy controls (P < 0.01), while there was
no difference between dose B (10mg/10mg), dose C (10
mg/5mg) and control patients [35]. When combining the
results of all patients receiving hydrocortisone replacement
for analysis (but not controls), there was a negative correl-
ation between total urinary cortisol metabolites with the
bone formation marker, PINP (r = − 0.39, p = 0.04),
Fig. 4b, and a trend towards significance with OC [1–
49] (r = − 0.35, p = 0.06), Fig. 4a. There was a negative
correlation between total urinary cortisol metabolites
and the bone remodelling ratio, PINP: CTX-I ratio
(r = − 0.41, p = 0.02), Fig. 4f.
As detailed in a previous publication [35], 11β-
HSD1 activity was increased across all dose regimens
compared to healthy controls and highest in dose A
(20mg/10mg). When combining the results of all pa-
tients receiving hydrocortisone replacement for ana-
lysis (but not controls), the urinary THF + alloTHF/
THE ratio, a measure of global 11β-HSD1 activity did
not correlate with any bone turnover markers. There
was no difference in UFF/UFE, a marker of 11β-
HSD2 activity, between the different HC doses and
no observed correlation between UFF/UFE, with any
bone turnover markers in the patient group.
The activities of the 5α and 5β-reductase enzymes
can be inferred from measuring the ratio of 5α over
5β-reduced steroid metabolites, i.e. 5α-THF/THF and
androsterone/etiocholanolone. There was a positive
correlation between the androsterone/etiocholanolone
ratio and the formation markers PINP (r = 0.35, p =
0.06) and OC [1–49] (r = 0.35, p = 0.06) and the
bone-remodelling index PINP:CTX-I ratio (r = 0.37,
p = 0.04). There were no significant correlations found
with bone resorption markers or with 5α-THF/THF,
Table 4.
Discussion
We report that serum cortisol, cortisone and urinary
total cortisol metabolites are associated with alterations
in bone turnover markers in patients with adrenal insuf-
ficiency receiving commonly used doses of hydrocorti-
sone replacement therapy. We also report that there is a
dose-response relationship between serum cortisone and
the dose of hydrocortisone and this impacts on markers
of bone turnover in patients receiving hydrocortisone
therapy. There is a greater impact of night-time cortisol
Table 1 Concentrations of bone turnover markers in patients and controls. Data are expressed as mean (standard deviation) or
median (interquartile ranges)
Dose A (n = 10)
20mg/10mg
Dose B (n = 10)
10mg/10mg
Dose C (n = 10)
10mg/5mg
Controls (n = 10)
PINP (μg/l) 54.9 (36.4–139.5) 71.6 (42.9–126.7) 102.4 (54.9–166.1) 45.65 (37.8–30.2
OC[1–49] (μg/l) 21.9 (19.1–42.3) 26.3 (20.5–39.3) 34.2 (23.7–43.4) 18.6 (15.7–30.2)
Bone ALP (μg/l) 16.5 (10.6) 15.5 (7.9) 14.4 (7.6) 12.1 (3.5)
CTX-I (μg/l) 0.51 (0.29–0.96) 0.47 (0.26–0.64) 0.58 (0.29–0.84) 0.32 (0.27–0.56)
TRACP5b (IU/l) 2.92 (2.27–3.76) 2.69 (2.27–3.53) 2.76 (2.07–3.09) 2.79 (2.64–2.97)
PINP:CTX-I ratio 137 (43.5) 181 (79.3) 208 (56) 136 (49.2)
OC [1–49] = osteocalcin, PINP Procollagen type 1 peptide, Bone ALP Bone alkaline phosphatase, CTX-I C terminal cross-linking telopeptide, TRACP5b Tartrate
resistant acid phosphatase 5b
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and cortisone exposure than day-time exposure on bone
turnover markers in patients receiving hydrocortisone
replacement therapy.
We found the values of cortisone to accord well with
previously published results for serum cortisone [43, 44].
Our study shows that serum cortisone fluctuates over
the day in patients receiving hydrocortisone therapy,
with the timing of peaks and troughs like those for corti-
sol. Cortisone excursions are also dependent on the dose
of hydrocortisone ingested and are significantly different
from those reported in healthy controls. While the over-
all concentrations of circulating cortisone may not be
Fig. 3 Correlation between circulating serum cortisone in all patients on hydrocortisone replacement with; Bone formation markers (a) OC [1–49], (b)
PINP, (c) Bone ALP and Bone resorption markers (d) CTX-I, (e) TRACP5b and (f) PINP: CTX ratio. OC [1–49] = osteocalcin; PINP = procollagen type 1
peptide; Bone ALP = bone alkaline phosphatase; CTX-I = C terminal cross-linking telopeptide; TRACP5b = tartrate resistant acid phosphatase 5b
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elevated compared to controls, we postulate that the
fluctuations at a tissue level may have a potential impact
on bone biology.
Previous studies have also reported cyclic variations in
serum cortisone however, these studies used radioimmuno-
assay for cortisone measurement [43, 44]. Immunoassays
have limited dynamic range particularly at lower concentra-
tions and show cross-reactivity with structurally related me-
tabolites. It has recently been recognized by the Endocrine
Society that the performance of some immunoassays meas-
uring cortisol and cortisone may be suboptimal for clinical
use [45]. LC-MS provides a gold standard measure by
which all routine assays are assessed [45]. Few studies have
determined the simultaneous fluctuations and relationship
of cortisol and cortisone by the gold standard method of
LC-MS/MS [46]. It is important to highlight that most of
serum cortisol is bound [80% bound to cortisol-binding
globulin (CBG) and 10% to albumin] and is therefore of
limited bioavailability. Serum cortisone binds with lower
affinity to CBG and therefore may potentially lead to
physiological glucocorticoid availability within tissues via
conversion to cortisol by 11β-HSD1 [47, 48].
The process of bone remodelling is complex and tar-
geted at multiple levels by glucocorticoids [33]. It is
understood that glucocorticoids affect the function of
multiple cell types, with the strongest evidence indicat-
ing osteoblasts as the main target [49]. The transcription
of osteocalcin, an osteoblast-specific gene, is suppressed
by glucocorticoids [50] and serum levels of osteocalcin
are reduced in patients receiving glucocorticoids [51,
52]. Our study supports these findings, as we observed a
significant negative correlation between serum cortisol
and cortisone and OC [1–49] in our patients on HC
replacement therapy.
There is limited data on the role of serum cortisone
on bone physiology. In a cross-sectional study of healthy
subjects (135 woman and 171 men), Cooper et al. found
a negative correlation between serum cortisone and
osteocalcin, which was stronger in men than women and
independent of serum cortisol [21]. Interestingly, we
found that night-time serum cortisone levels negatively
correlated with bone formation markers, OC [1–49] and
PINP, as did nocturnal serum cortisol with OC [1–49]
and PINP but no significant correlations were seen be-
tween day-time serum cortisone or cortisol with any
bone turnover markers. Bone turnover has a circadian
rhythm in humans, with bone resorption and, to a lesser
extent, bone formation increasing at night [53, 54].
Several studies have examined the role of cortisol in me-
diating the circadian rhythm of bone turnover, with con-
flicting results. Neilson et al. found that single oral doses
of prednisolone (2.5 and 10mg) given to healthy subjects
inhibited and even reversed the nocturnal rise in serum
osteocalcin levels [55]. Schlemmer et al. reported that
hydrocortisone administered orally in divided doses to
Table 2 Association of circulating serum cortisone (AUC) and
total cortisol (AUC) with bone turnover markers in patients
receiving hydrocortisone
All patients on HC
Spearman Correlation (r)
Cortisone (AUC)
r value, (p value)
Cortisol (AUC)
r value, (p value)
Bone Formation
OC[1–49] (μg/l) −0.42, (p = 0.02)* − 0.57, (p = 0.002)*
PINP (μg/l) −0.49, (p = 0.01)* −0.36, (p = 0.0689)
Bone ALP (μg/l) 0.05, (p = 0.82) −0.06, (p = 0.78)
Bone Resorption
CTX-I (μg/l) −0.34, (p = 0.08) −0.5, (p = 0.008)*
TRACP5b (IU/l) − 0.18, (p = 0.38) −0.2323, (p = 0.24)
PINP: CTX-I ratio − 0.39, (p = 0.04)* −0.4756, (p = 0.01)*
HC Hydrocortisone, AUC Area under curve, OC [1–49] = osteocalcin, PINP
Procollagen type 1 peptide, Bone ALP Bone alkaline phosphatase, CTX-I C
terminal cross-linking telopeptide, TRACP5b Tartrate resistant acid
phosphatase 5b
*p < 0.05
Table 3 Association of circulating day-time and night-time serum cortisone (AUC) and total cortisol (AUC) with bone turnover
markers in patients receiving hydrocortisone




r value, (p value)
Day-time Cortisol (AUC)
r value, (p value)
Night-time Cortisone (AUC)
r value, (p value)
Night-time Cortisol (AUC)
r value, (p value)
Bone Formation
OC[1–49] (μg/l) −0.23, (p = 0.25) −0.23, (p = 0.25) −0.41, (p = 0.03)* −0.36, (p = 0.07)
PINP (μg/l) − 0.28, (p = 0.16) −0.28, (p = 0.16) −0.34, (p = 0.08) −0.38, (p = 0.04)*
Bone ALP (μg/l) − 0.08, (p = 0.7) −0.0778, (p = 0.7) − 0.03, (p = 0.9) 0.013, (p = 0.95)
Bone Resorption
CTX-I (μg/l) − 0.14, (p = 0.50) −0.14, (p = 0.50) −0.34, (p = 0.08) −0.28, (p = 0.16)
TRACP5b (IU/l) − 0.19, (p = 0.32) −0.19, (p = 0.32) 0.021, (p = 0.92) −0.12, (p = 0.55)
PINP:CTX-I ratio − 0.28, (p = 0.14) −0.29, (p = 0.14) −0.12, (p = 0.55) −0.29, (p = 0.13)
HC Hydrocortisone, AUC Area under curve, OC [1–49] = osteocalcin, PINP Procollagen type 1 peptide, Bone ALP Bone alkaline phosphatase, CTX-I C terminal cross-
linking telopeptide, TRACP5b Tartrate resistant acid phosphatase 5b
*p < 0.05
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patients with adrenal insufficiency did not prevent the
nocturnal increase in bone resorption [27]. Heshmati
et al. inhibited endogenous cortisol synthesis using
metyrapone and infused cortisol at either a variable rate
(to mimic the physiological circadian variation in serum
cortisol) or at a constant rate (to eliminate the cortisol
rhythm) and assessed the circadian variation in bone
formation and bone resorption under these two condi-
tions [28]. They found that the morning rise in serum
cortisol was responsible for the day-time nadir in serum
Fig. 4 Correlation between total urinary cortisol metabolites in all patients on HC replacement with; Bone formation markers (a) OC [1–49], (b)
PINP, (c) Bone ALP and Bone resorption markers (d) CTX-I, (e) TRACP5b, (d) PINP: CTX ratio. Total urinary F metabolites = Total urinary cortisol
metabolites; OC [1–49] = osteocalcin; PINP = procollagen type 1 peptide; Bone ALP = bone alkaline phosphatase; CTX-I = C terminal cross-linking
telopeptide; TRACP5b = tartrate resistant acid phosphatase 5b
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osteocalcin levels and conversely the nocturnal increase
in serum osteocalcin levels was a consequence of the
declining evening and night-time cortisol levels. This
suggests that nocturnal glucocorticoid exposure has
potentially a greater influence on bone turnover, as was
observed in our study population. We believe this has
significant clinical implications with regard to the timing
of glucocorticoid dosing, as patients (particularly those
taking thrice-daily regimens) may be recommended to
take their final hydrocortisone dose of the day in the late
afternoon/ early evening and some patients with con-
genital adrenal hyperplasia have historically received
glucocorticoids late at night to impact on the nocturnal
rise in adrenal androgens in response to the nocturnal
ACTH surge. If glucocorticoids are taken later in the
day it may lead to higher levels of cortisol/ cortisone
during night-time hours and thus have a greater negative
impact on bone metabolism [56].
In our study, patients who were on hydrocortisone
therapy had an increase in total urinary cortisol metabo-
lites, which negatively correlated with bone formation
markers PINP and OC [1–49]. This observation provides
evidence that exogenous hydrocortisone is not simply
excreted by the kidneys but is metabolized at a cellular
level, leading to enhanced glucocorticoid tissue exposure
and potentially deleterious effects on bone turnover.
Tissue exposure to glucocorticoids is, in part, determined
at the pre-receptor level; where 11β-hydroxysteroid en-
zymes play a central role. 11β-HSD1 is the predominant
isozyme expressed in normal adult osteoblasts and osteo-
clasts, converting inactive cortisone to cortisol, and deter-
mines their exposure to active glucocorticoids. Cooper
et al. previously observed that urinary measures of 11β-
HSD1 activity (THF + 5αTHF/THE) predicted the reduc-
tion in bone formation markers, OC and PINP, in 20
healthy adult patients post oral prednisolone therapy (10
mg daily for 7 days) [57]. We have previously shown that
in patients receiving oral HC replacement, there was an
increase in 11β-HSD1 activity compared to the control
group, however, in this study, we did not observe a signifi-
cant correlation with urinary markers of 11β-HSD1 activity
and bone formation markers [35]. This may reflect the
lower glucocorticoid dose in our study population com-
pared to the study by Cooper et al., and the fact that our
patients were on stable hydrocortisone therapy for many
years, compared to the study by Cooper et al. who mea-
sured the effect of a short exposure to high dose gluco-
corticoid therapy. The risk of bone loss tends to be highest
in the acute phase post commencement of glucocorticoid
therapy followed by a slower, steady-state of loss with
chronic glucocorticoid use, as would have been the case in
our patients.
In contrast to the enzyme 11β-HSD1, the A-ring re-
ductases (5α-reductase and 5β-reductases) reduce local
glucocorticoid availability by inactivating cortisol [58]. 5
alpha-reductase activities have been found in vitro in
osteoblast-like cells [59]. We observed a positive correl-
ation between 5α-reductase activity as measured by the
urinary 5α THF/THF and ANDRO/ETIO ratios, with
bone formation markers PINP and OC [1–49]. This
would indicate that increased activity of 5-alpha reduc-
tases is associated with increased metabolism of active
glucocorticoids to inactive glucocorticoids which is
associated with an increase in bone formation. This may
have implications for the bone health of patients who
receive 5-alpha reductase inhibitors [60–63].
Conclusion
In conclusion, changes in circulating cortisone and
cortisol metabolites were associated with alterations
in bone turnover. While further data is required, our
data raises important questions regarding total daily
dose, the impact of timing of glucocorticoid doses on
bone health and the importance of bone-specific me-
tabolism of glucocorticoids.
Table 4 Association of urinary steroid metabolites with bone turnover markers in patients receiving hydrocortisone. Total urinary F
metabolites = Total urinary cortisol metabolites; Andro = androsterone; Etio = etiocholanolone *p < 0.05
All patients on HC replacement
(n = 30)
Urinary metabolites:
r value (p value)
Total urinary F metabolites THF + aTHF /THE UFF/UFE 5a THF/THF Andro/Etio
Bone Formation
OC[1–49] (μg/l) −0.35, (p = 0.06) − 0.12, (p = 0.53) 0.09, (p = 0.62) 0.35, (p = 0.06) 0.5, (p = 0.004)*
PINP (μg/l) −0.39, (p = 0.04)* −0.18, (p = 0.32) 0.08, (p = 0.66) 0.35, (p = 0.06) 0.5, (p = 0.004)*
Bone ALP (μg/l) −0.02, (p = 0.93) −0.18, (p = 0.35) 0.29, (p = 0.11) −0.07, (p = 0.7) 0.13, (p = 0.49)
Bone Resorption
CTX-I (μg/l) −0.15, (p = 0.42) −0.18, (p = 0.35) 0.17, (p = 0.36) 0.17, (p = 0.38) 0.30, (p = 0.1)
TRACP5b (IU/l) −0.14, (p = 0.46) −0.31, (p = 0.09) 0.18, (p = 0.35) −0.8, (p = 0.66) 0.18, (p = 0.33)
PINP: CTX-I ratio −0.41, (p = 0.02)* −0.15, (p = 0.45) − 0.04, (p = 0.83) 0.37, (p = 0.04)* 0.58, (p = 0.008)*
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